The Pokémon Company International and Fathom Events Bring Pokémon the Movie: I Choose You! to Theaters for a Two-Day Cinema Event
The new animated film Pokémon the Movie: I Choose You!, based on the globally popular Pokémon brand, is coming to movie theaters around the world for two days this November. The Pokémon Company International announced today that it has entered into an agreement with Fathom Events, the recognized leader in event cinema distribution, for international theatrical rights (outside of Asia) to the highly-anticipated movie.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20170731005842/en/
Pokémon the Movie: I Choose You! (Photo: Business Wire)
Pokémon the Movie: I Choose You! is an origin story highlighting Ash and Pikachu’s first meeting and their adventures as they search for the Legendary Pokémon Ho-Oh. The iconic pair encounter familiar faces along the way, new characters including Trainers Verity and Sorrel, and even a mysterious new Mythical Pokémon, Marshadow. Challenges and epic Pokémon battles abound in this unique new story about the beginning of one of the most beloved friendships in popular culture.
“As an origin story, Pokémon the Movie: I Choose You! is the perfect way for a new generation of Pokémon fans to experience the beginning of Ash and Pikachu’s friendship, and it offers longtime fans an exciting new look into the start of their epic adventures,” said Colin Palmer, Vice President of Marketing at The Pokémon Company International. “We’re excited to work with Fathom Events, whose expertise in unique theatrical event activations will offer families and fans the opportunity to come together and experience the excitement of Pokémon animation on the big screen.”
Pokémon the Movie: I Choose You! will be shown in movie theaters for two days only, on Sunday, November 5, and Monday, November 6, 2017, in select international markets. More details, including screening times and special offers, will be available soon. The movie is already winning over crowds of moviegoers in Japan, where the franchise began, as it opened at the top of the charts for its first weekend.
“Fathom Events is thrilled to work with The Pokémon Company International to bring Pokémon the Movie: I Choose You! to the U.S. and international event cinema markets,” Fathom Events CEO-elect Ray Nutt said. “We can’t wait to deliver a high-caliber Pokémon cinema event that fans around the world won’t want to miss.”
More information, including participating theater locations, ticketing dates, and event details, will be available soon on www.FathomEvents.com. Parents and fans can visit the site now to sign up and receive updates and details about the upcoming limited theatrical release.
To learn more about Pokémon animation, visit www.Pokemon.com and join the conversation on social media with #PokemonIChooseYou.
About Pokémon
The Pokémon Company International, a subsidiary of The Pokémon Company in Japan, manages the property outside of Asia and is responsible for brand management, licensing and marketing, the Pokémon Trading Card Game, the animated TV series, home entertainment, and the official Pokémon website. Pokémon was launched in Japan in 1996 and today is one of the most popular children’s entertainment properties in the world. For more information, visit www.pokemon.com.
About Fathom Events
Fathom Events is recognized as the leading domestic distributor of event cinema with participating affiliate theaters in all 100 of the top Designated Market Areas®, and ranks as one of the largest overall distributors of content to movie theaters. Owned by AMC Entertainment Inc. (NYSE: AMC), Cinemark Holdings, Inc. (NYSE: CNK) and Regal Entertainment Group (NYSE: RGC) (known collectively as AC JV, LLC), Fathom Events offers a variety of one-of-a-kind entertainment events such as live, high-definition performances of the Metropolitan Opera, dance and theatre productions like the Bolshoi Ballet and National Theatre Live, sporting events like “Canelo Álvarez vs. Julio César Chávez, Jr.,” concerts with artists like Michael Bublé, Rush and Mötley Crüe, the yearlong TCM Big Screen Classics film series, inspirational events such as To Joey With Love and Facing Darkness, and anime titles such as Princess Mononoke and Spirited Away. Fathom Events takes audiences behind the scenes and offers unique extras including audience Q&As, backstage footage and interviews with cast and crew, creating the ultimate VIP experience. Fathom Events’ live digital broadcast network (“DBN”) is the largest cinema broadcast network in North America, bringing live and pre-recorded events to 897 locations and 1,387 screens in 181 DMAs. For more information, visit www.fathomevents.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170731005842/en/
Contact information
Fathom Events
Jessica Nelson, 720-262-2753
jnelson@fathomevents.com
or
Katherine
Schwappach, 720-262-2713
kschwappach@fathomevents.com
or
The
Pokémon Company International
Daniel Benkwitt, 425-229-6070
d.benkwitt@pokemon.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK ® , a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 09:03:00 EEST | Press release
Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least one non-class I mutation, meaning more patients would be eligible for a medicine that gets them closer to normal levels of sweat chloride,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. “CFTR modulators have already revolutionized the way we treat CF and I am encoura
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 08:02:00 EEST | Press release
Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization and further development of pridopidine in Europe and other select markets. Pridopidine is a potent and highly selective, orally administered sigma-1 receptor (S1R) agonist designed to regulate key neuroprotective mechanisms often impaired in neurodegenerative diseases such as HD and ALS. Under the terms of the agreement, Prilenia will receive an upfront payment of approximately €80 million plus up to €45 million in near-term development, regulatory, and commercial milestones. The total deal is valued at up to approximately €500 million in upfront and total milestone payments. In addition, Prilenia will receive tiered double-digit royalties on
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 08:00:00 EEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 12:36:00 EEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 20:00:00 EEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom